Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
75 results about "Dipeptidyl peptidase-4 inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2.
Administration of dipeptidyl peptidase inhibitors
InactiveUS20070060530A1Convenient treatmentEliminate side effectsBiocidePeptide/protein ingredientsDipeptidyl peptidaseBenzonitrile
Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.
Owner:TAKEDA PHARMA CO LTD
Dipeptidyl peptidase inhibitors
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C═NR4, and L, X, Z, R2 and R3 are as defined herein.
Owner:TAKEDA PHARMA CO LTD
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility.
Owner:SMITHKLINE BECKMAN CORP
3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Owner:MERCK SHARP & DOHME LLC
New effectors of dipeptidyl peptidase iv for topical use
InactiveUS20030092630A2Reduced activityOrganic active ingredientsPeptide/protein ingredientsDiseaseSide chain
Abstract of Disclosure The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain;B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g / mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine. The invention further relates to the use of said compounds for targeted intervention in local immunological processes (chemotaxis, inflammatory processes, autoimmune diseases), as well as effective and targeted treatment of pathophysiological and physiological processes related thereto (psoriasis, periodontitis, arthritis, allergies, inflammation), inter alia.
Owner:VIVORYON THERAPEUTICS NV
Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Owner:MERCK SHARP & DOHME CORP
Administration of dipeptidyl peptidase inhibitors
InactiveUS20070060528A1Improve blood supplyIncrease supplyBiocideNervous disorderDipeptidyl peptidaseBenzonitrile
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.
Owner:TAKEDA PHARMA CO LTD
Dipeptidyl peptidase inhibitors
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and othe S9 proteases that comprise a compound comprising the formula: wherein Q is selected from the group consisting of CO, SO, SO2, or C=NR9; and R1, R2, R3 and R4 as defined herein.
Owner:QUALCOMM INC +2
Dipeptidyl peptidase inhibitors
Owner:TAKEDA PHARMA CO LTD
Dipeptidyl peptidase inhibitors
InactiveUS20040259870A1Organic active ingredientsImpression capsProteinase activityDipeptidyl peptidase
Owner:SYRRX +1
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Owner:MERCK SHARP & DOHME LLC
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
InactiveUS7109347B2Reduce expressionReduce adhesionBiocideDipeptide ingredientsAnticarcinogenLymphatic Spread
Owner:VIVORYON THERAPEUTICS NV
Pharmaceutical Compositions of Combinations of Dipeptidyl Peptidase-4 Inhibitors With Metformin
Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Owner:MERCK SHARP & DOHME LLC
New solid forms of trelagliptin and manufacturing method and purpose thereof
InactiveCN104003975AEasy to makeEasy to prepareOrganic active ingredientsNervous disorderDiseaseDipeptidyl-Peptidase IV Inhibitors
The present invention relates to solid forms of trelagliptin, a preparation method therefor and applications thereof, and relates specifically to six new solid forms of the dipeptidyl peptidase-4 inhibitor trelagliptin and preparation methods therefor, as well as to pharmaceutical compositions comprising said solid forms of trelagliptin, and uses of same in the preparation of medicines for the treatment of diseases mediated by dipeptidyl peptidase-4.
Owner:SICHUAN HAISCO PHARMA CO LTD
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
ActiveCN101365432APeptide/protein ingredientsMetabolism disorderDipeptidyl peptidaseDipeptidyl peptidase-4 inhibitor
Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Owner:MERCK SHARP & DOHME BV
Pyrrolidines as dipeptidyl peptidase inhibitors
The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility
Owner:SMITHKLINE BECKMAN CORP
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
InactiveUS20050107308A1Reduce expressionLower blood pressureBiocidePeptide/protein ingredientsDipeptidyl-Peptidase IV InhibitorsDipeptidyl peptidase-4 inhibitor
The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.
Owner:PROSIDION LIMITED
Administration of Dipeptidyl Peptidase Inhibitors
InactiveUS20110212982A1Convenient treatmentEliminate side effectsBiocideNervous disorderDipeptidyl peptidaseBenzonitrile
Owner:TAKEDA PHARMA CO LTD
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Owner:MERCK SHARP & DOHME LLC
Dipeptidyl peptidase inhibitors for the treatment of diabetes
Compounds having Formula I, including pharmaceutically acceptable salts and prodrugs thereof: (Formula I) are inhibitors of the dipep tidyl peptidase-IV enzyme (DP-IV), and are useful in the treatment of DP-IV mediated diseases and conditions, such as non-insulin dependent diabetes mellitus.
Owner:MERCK SHARP & DOHME CORP
Dipeptidyl peptidase inhibitors
Owner:TAKEDA PHARMA CO LTD
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Owner:MERCK SHARP & DOHME LLC
Beta-amino tetrahydropyrazine, tetrahydropyrimidine and tetrahydropyridine used as dipeptidy peptidase inhibitors for curing or preventing diabetes
The invention relates to beta-amino tetrahydropyrazine, tetrahydropyrimidine and tetrahydropyridine used as dipeptidy peptidase inhibitors for curing or preventing diabetes. Each variable quantity is defined as the application specification. The compounds are the inhibitors of dipeptidy peptidase-IV enzyme ('DP-IV inhibitors') and can be used for curing or preventing diseases relevant to the dipeptidy peptidase-IV enzyme, such as the diabetes, particularly the II-type diabete. The invention also relates to a medicinal composition comprising the compounds and application of the compounds and the composition in preventing or curing the diseases relevant to the dipeptidy peptidase-IV enzyme.
Owner:CGENETECH (SUZHOU CHINA) CO LTD
Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
InactiveUS20100291020A1Lower levelImprove insulin resistanceBiocideOrganic chemistryDiseaseDipeptidyl peptidase
The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved.
Owner:LUPIN LTD
Crystal form of oxalate of dipeptidyl peptidase inhibitor and preparation method and application thereof
ActiveCN102432599ALow costIncrease humidityOrganic active ingredientsOrganic chemistryOxalateDipeptidyl peptidase
The invention discloses a novel crystal form of oxalate of dipeptidyl peptidase inhibitor, namely, (s)-1-(2-(2-(3-(3,4-dimethoxyphenyl)-2-oxo-1-imidazolidinyl)ethylamino)acetyl)-2-cyanpyrrolidine oxalate. In X-ray powder diffraction of the crystal form, characteristic peaks occur at 2 theta diffraction angles of 4.5+ / -0.1, 5.5+ / -0.1, 9.0+ / -0.1, 10.9+ / -0.1, 16.4+ / -0.1, 17.7+ / -0.1, 18.1+ / -0.1, 22.0+ / -0.1, 22.7+ / -0.1, 25.6+ / -0.1, 28.1+ / -0.1, 28.4+ / -0.1 and 32.0+ / -0.1. The crystal form disclosed by the invention is superior to the original oxalate in stability, and is more stable for light, heat and humidity and convenient to store and transport; the cost of the DPP-IV (dipeptidyl peptidase-IV) inhibitor in transportation and preservation processes is decreased; and the safety of the product is further guaranteed.
Owner:CHENGDU DIAO PHARMA GROUP
Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
InactiveUS7230002B2Reduce riskIncrease the number ofBiocideOrganic chemistryDipeptidyl peptidaseDipeptidyl-Peptidase IV Inhibitors
The present invention relates to novel dipeptidyl peptidase IV (DPP-IV) inhibitors their analogs, isomers, pharmaceutical compositions, therapeutic uses and methods of making the same.
Owner:GLENMARK PHARMACEUTICALS LIMITED
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
InactiveUS20140093564A1BiocideMetabolism disorderDipeptidyl peptidaseDipeptidyl peptidase-4 inhibitor
The present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor), or a pharmaceutically acceptable salt thereof, and simvastatin, or pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes and hypercholesterolemia with such pharmaceutical compositions. In particular, the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and simvastatin.
Owner:MERCK SHARP & DOHME LTD
Piperazinoltriazole derivatives
The invention provides piperazinoltriazole derivatives, in particular dipeptidyl peptidase IV inhibitors shown by a formula (I) below. The substituents in the formula are defined in the description. The compounds can be used for treating or preventing diseases associated with dipeptidyl peptidase IV, such as diabetes, obesity and hyperlipidemia. The invention also provides methods for preparing the compounds shown by the formula (I), pharmaceutically acceptable salts of the compounds and medicinal compositions and the use of the compounds, the pharmaceutically acceptable salts of the compounds and the medicinal compositions in the preparation of medicaments for treating or preventing diseases associated with dipeptidyl peptidase IV.
Owner:SHANGHAI SUN SAIL PHARMA SCI & TECH CO LTD
Dipeptidyl peptidase inhibitors for the treatment of diabetes
Compounds having Formula I, including pharmaceutically acceptable salts and prodrugs thereof: (I) are inhibitors of the dipeptidyl peptidase-IV enzyme (DP-IV), and are useful in the treatment of DP-IV mediated diseases and conditions, such as non-insulin dependent diabetes mellitus
Owner:MERCK SHARP & DOHME CORP
Drug for treating hepatocellular carcinoma and application of glucagon-like peptide-1 receptor stimulant and/or dipeptidyl peptidase 4 inhibitor
InactiveCN107050459APrevent proliferationPromote apoptosisOrganic active ingredientsPeptide/protein ingredientsDifferential effectsDipeptidyl peptidase
The invention provides a drug for treating hepatocellular carcinoma. The drug comprises a glucagon-like peptide-1 receptor stimulant and / or a dipeptidyl peptidase 4 inhibitor. The invention further provides application of the glucagon-like peptide-1 receptor stimulant and / or dipeptidyl peptidase 4 inhibitor to preparation of a drug for preventing or treating hepatocellular carcinoma, to preparation of a drug for liver function recovery after liver transplantation, and to preparation of a drug for preventing liver cancer relapse after liver transplantation. The glucagon-like peptide-1 receptor stimulant and / or dipeptidyl peptidase 4 inhibitor generates a differential effect in a tissue specificity way, so as to inhibit cancer cell proliferation and promote cancer cell apoptosis, meanwhile, liver cells are protected against apoptosis, so that obesity-dependent liver cancer or non-dependent liver cancer can be treated or weakened.
Owner:SUN YAT SEN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com